Scientists from the Janssen Immunology Therapeutic Area and researchers from Mount Sinai will investigate disease triggers, identify new opportunities for therapeutic interventions and establish diagnostics to facilitate precision medicine and predictive biomarkers.
"Research alliances such as these allow us to develop, patent, license and translate laboratory breakthroughs into clinical applications," said Dennis Charney, M.D., Anne and Joel Ehrenkranz dean at Mount Sinai and executive vice president for academic affairs.
The collaboration will focus on building a Molecular Interaction Network of Disease (MIND) in IBD with the breadth and depth to yield therapeutic hypotheses to be tested in vitro and in vivo. Using preclinical models, clinical study data and patient samples, researchers, computational biologists and translational medicine scientists will develop clinical methodologies to test hypotheses and identify potential therapeutic candidates.
